Combined treatment with inhibitors of erbb receptors and hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo

HIGHLIGHTS

• who: Roberto Bei from the DMSO and Sulforhodamine B (SRB) were purchased from Sigma-Aldrich (Milan, Italy have published the article: Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo, in the Journal: (JOURNAL)
• what: The aim of this study was to evaluate the effects of inhibitors of_(GANT-61) and ErbB (Afatinib)-mediated when used alone or in combination on growth cell cycle cell death and autophagy modulation of molecules involved in transduction . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.